Goldman Sachs Starts TCR2 Therapeutics (TCRR) at Neutral

January 19, 2022 4:06 AM EST
Get Alerts TCRR Hot Sheet
Price: $2.91 --0%

Rating Summary:
    7 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 21 | New: 52
Trade Now! 
Join SI Premium – FREE

Goldman Sachs analyst Madhu Kumar initiates coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Neutral rating and a price target of $5.00.

For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.

Shares of TCR2 Therapeutics closed at $3.76 yesterday.

You May Also Be Interested In

Related Categories

New Coverage